Celadon Pharmaceuticals (LSE:CEL) Long-Term Capital Lease Obligation : €5.37 Mil (As of Dec. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Celadon Pharmaceuticals Long-Term Capital Lease Obligation?

Celadon Pharmaceuticals's Long-Term Capital Lease Obligation for the quarter that ended in Dec. 2023 was €5.37 Mil.

Celadon Pharmaceuticals's quarterly Long-Term Capital Lease Obligation increased from Dec. 2022 (€5.22 Mil) to Jun. 2023 (€5.32 Mil) and increased from Jun. 2023 (€5.32 Mil) to Dec. 2023 (€5.37 Mil).

Celadon Pharmaceuticals's annual Long-Term Capital Lease Obligation increased from Dec. 2021 (€0.00 Mil) to Dec. 2022 (€5.22 Mil) and increased from Dec. 2022 (€5.22 Mil) to Dec. 2023 (€5.37 Mil).

Celadon Pharmaceuticals Long-Term Capital Lease Obligation Historical Data

The historical data trend for Celadon Pharmaceuticals's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Celadon Pharmaceuticals Long-Term Capital Lease Obligation Chart

Celadon Pharmaceuticals Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Long-Term Capital Lease Obligation

2.99

3.18

5.22

5.37

Celadon Pharmaceuticals Semi-Annual Data
	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial			-	5.06	5.22	5.32	5.37

Celadon Pharmaceuticals (LSE:CEL) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Celadon Pharmaceuticals Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Celadon Pharmaceuticals's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Celadon Pharmaceuticals (LSE:CEL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Celadon Pharmaceuticals PLC (LSE:CEL) » Definitions » Long-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

N/A

Address

32-33 Cowcross Street, London, GBR, EC1M 6DF

Website

https://www.celadonpharma.co.uk

Celadon Pharmaceuticals PLC focuses on growing indoor hydroponic high-quality cannabis initially for use within the chronic pain market. It has two reportable segments Celadon is a Build of grow facilities, growing medical grade cannabis and research in the GMP lab, and Harley Street (CPC) is a clinical study into the pain relief benefits of medicinal cannabis.

Celadon Pharmaceuticals (LSE:CEL) Headlines

No Headlines